Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AZUL SAAZUL · Entity 4770 | Member of Strategy Committee | June 15, 2026 | June 17, 2026 |
| Keenova Therapeutics plcNONE · Entity 28960 | Director | July 15, 2026 | July 18, 2026 |
| QVC Group, Inc.QVCG · Entity 1478 | Director | August 06, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AZUL SA
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 980,860 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 980,860 · Balance 980,860 F1: Represents a grant of 980,860 rights to acquire common shares pursuant to the terms of the Issuer's Restricted Shares Granting Plan and applicable documentation thereunder ("Restricted Shares"). The Restricted Shares vest over four years as follows: approximately 40% vested on the grant date and approximately 20% will vest on each of May 5, 2027, May 5, 2028 and May 5, 2029, contingent on the reporting person's continued service on each applicable vesting date F2: In the event that the Issuer does not hold sufficient treasury shares for the settlement of the Restricted Shares on the applicable vesting date, the Reporting Person will be required to subscribe for the Restricted Shares for a nominal price of R$1.00 (one Brazilian real) for all Restricted Shares subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of 980,860 rights to acquire common shares pursuant to the terms of the Issuer's Restricted Shares Granting Plan and applicable documentation thereunder ("Restricted Shares"). The Restricted Shares vest over four years as follows: approximately 40% vested on the grant date and approximately 20% will vest on each of May 5, 2027, May 5, 2028 and May 5, 2029, contingent on the reporting person's continued service on each applicable vesting date
F2: In the event that the Issuer does not hold sufficient treasury shares for the settlement of the Restricted Shares on the applicable vesting date, the Reporting Person will be required to subscribe for the Restricted Shares for a nominal price of R$1.00 (one Brazilian real) for all Restricted Shares subject to vesting.
Keenova Therapeutics plc
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 39,078 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 4,406 · Balance 39,078 F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
QVC Group, Inc.
Report date August 06, 2026 · Filed August 06, 2026
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 18, 2026 01:56 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 4,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-084778 · tm2620763-7_4seq1.xml · derivative · entry 1 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,078 Underlying: Ordinary Shares · 4,406 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 23:06 UTC | AZUL SA AZUL · Entity 4770 | GrantCommon Shares | 980,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-26-000903 · form4.xml · nonDerivative · entry 1 Zinman Jon · CIK 0002001886 · Member of Strategy Committee 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 980,860 F1 · shares: Represents a grant of 980,860 rights to acquire common shares pursuant to the terms of the Issuer's Restricted Shares Granting Plan and applicable documentation thereunder ("Restricted Shares"). The Restricted Shares vest over four years as follows: approximately 40% vested on the grant date and approximately 20% will vest on each of May 5, 2027, May 5, 2028 and May 5, 2029, contingent on the reporting person's continued service on each applicable vesting date F2 · price: In the event that the Issuer does not hold sufficient treasury shares for the settlement of the Restricted Shares on the applicable vesting date, the Reporting Person will be required to subscribe for the Restricted Shares for a nominal price of R$1.00 (one Brazilian real) for all Restricted Shares subject to vesting. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 4,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070519 · tm2616870-2_4seq1.xml · derivative · entry 2 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,672 Underlying: Ordinary Shares · 4,882 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. F3 · derivative.exercise_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F3 · derivative.expiration_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 4,882 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-070519 · tm2616870-2_4seq1.xml · nonDerivative · entry 1 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JZ Advisors LLC Disclosed balance after: 12,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. F2 · ownership.direct: Shares are held directly by JZ Advisors LLC, a limited liability company, of which the Reporting Person is a 100% owner and managing member. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 01:59 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 3,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-019929 · tm267115-8_4seq1.xml · derivative · entry 1 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,554 Underlying: Ordinary Shares · 3,984 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: Each RSU will fully vest on February 23, 2027. F2 · derivative.expiration_date: Each RSU will fully vest on February 23, 2027. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:05 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 4,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-000785 · tm261751-8_4seq1.xml · derivative · entry 2 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,570 Underlying: Ordinary Shares · 4,384 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. F3 · derivative.exercise_date: On February 19, 2024, the Reporting Person was granted 10,942 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below. F3 · derivative.expiration_date: On February 19, 2024, the Reporting Person was granted 10,942 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below. F4 · balance_after: Reflects that the Reporting Person received 6,711 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:05 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 4,384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-000785 · tm261751-8_4seq1.xml · nonDerivative · entry 1 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JZ Advisors LLC Disclosed balance after: 8,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. F2 · ownership.direct: Shares are held directly by JZ Advisors LLC, a limited liability company, of which the Reporting Person is a 100% owner and managing member. Read SEC document |
| August 14, 2025 Filed Aug 19, 2025 01:07 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 4,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-079950 · tm2523680-9_4seq1.xml · derivative · entry 1 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,243 Underlying: Ordinary Shares · 4,062 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| July 31, 2025 Filed Aug 5, 2025 00:53 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 21,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-073797 · tm2522414-27_4seq1.xml · derivative · entry 1 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,181 Underlying: Ordinary Shares · 21,886 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. F2 · derivative.exercise_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026. F2 · derivative.expiration_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:05 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 3,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000378 · tm2432211-16_4seq1.xml · derivative · entry 2 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,295 Underlying: Ordinary Shares · 3,647 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. F3 · derivative.exercise_date: On February 19, 2024, the reporting person was granted 10,942 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. F3 · derivative.expiration_date: On February 19, 2024, the reporting person was granted 10,942 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:05 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 3,647 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000378 · tm2432211-16_4seq1.xml · nonDerivative · entry 1 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JZ Advisors LLC Disclosed balance after: 3,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. F2 · ownership.direct: Shares are held directly by JZ Advisors LLC, a limited liability company, of which the reporting person is a 100% owner and managing member. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 21:20 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 10,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-025536 · tm245307-19_4seq1.xml · derivative · entry 1 Zinman Jon · CIK 0002001886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,942 Underlying: Ordinary Shares · 10,942 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit (the "RSU") will be settled in ordinary shares of the issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. F2 · derivative.expiration_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. F3 · ownership.direct: The Reporting Person is an employee of Silver Point Capital, L.P. ("Silver Point"). Mr. Zinman has an understanding with Silver Point pursuant to which he will hold any compensation received as a director for the benefit of Silver Point and certain of its affiliates. Mr. Zinman disclaims beneficial ownership of any of the Issuer's securities held by Silver Point or its affiliates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.